Most researchers agree that expanding the clinical application of RDW to include erythrocyte fragmentation, poor nutritional status, hypertension, dyslipidemia, and erythropoietin abnormalities is more appropriate than restricting the traditional application of RDW to the early detection of anemia (39). This evidence concerns the gene EPO and metabolic syndrome.